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cost of each stage of kidney disease according scheduled visits in each condition, 
and, therefore, to calculate the economic burden of one year dialysis for the Spanish 
Health System, to check the advantage of a treatment that could delay the disease 
progression of ADPKD. Methods: The model was based in normal practice of a 
specific hospital, selected for it’s expertise within ADPKD. To build the model the 
following figures were provided: Hospital costs (number of expected healthcare 
provider visits, analytics, image diagnosis), and other expected costs (such ambu-
lance transport and concomitant treatments for hypertension, hypercholester-
olemia, hyperuricemia, pain, infections, and haematuria). In addition to this, costs 
from the patient’s perspective, namely medication and transport costs were also 
analysed. Results: The annual cost for dialysis patients in Hospital La Paz, and 
Madrid Province, in general, is 56,028 euros (43,980.00 € for Hospital costs, up to 600 
€ for medication, and 11,448 € for ambulance transport) , while the rest of Chronic 
Kidney Disease stages (CKD stages 1-4) range annually between 809-1.551 € (Hospital 
costs and medication). Therefore, avoiding 1 year of dialysis will represent around 
54,800 € savings. ADPKD patients cover additional expenses (up to 350 € for medi-
cation and 8-195 € for transport, annually). ConClusions: Dialysis extensively 
increases the economic burden of ADPKD, this is mainly seen in the healthcare 
system. ADPKD patients are faced with medication costs and travel expenses, as 
well as other incommodities and non-calculated indirect costs. Therefore, a treat-
ment able to delay the disease progression represents an important step towards 
patient wellbeing and big savings for the Health System
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objeCtives: The cross sectional study aims to estimate the impact of socio-
economic determinants, such as education and employment status, on the social 
cost of a patient with chronic kidney disease (CKD) stage IV and V pre-dialyses in 
Italy Methods: Individual socio-economic and clinical data have been collected 
for all adult outpatients in charge of 14 main Hospitals Centers in Tuscany Region 
during 7 weeks between 2012 and 2013. Direct medical costs have been estimated 
using tariff for laboratory test, diagnostic exams, visits and hospitalization and 
price for drugs. The cost of diet, patients and caregivers travel expenses, formal and 
informal care have been evaluated as direct non medical costs. The human capital 
approach has been used for estimating the loss of productivity of patients and 
caregivers. The incremental effects of socio-economic determinants on social cost 
of CKD were estimated by multivariate Generalized Linear Models (log link, Gamma 
family) adjusting for gender, age and stage of disease. Results: No qualification 
and low levels of educations and non-working status characterized, respectively, 
the 54% and 89% of 484 patients enrolled. The raw estimated mean annual social 
costs were € 9,855 (± € 6,826) per patient with CKD. Direct medical costs amounted 
to € 4,352 (± 4,071), representing the 44% of the overall cost, while direct non medi-
cal costs and indirect costs accounted for 30% and 26% (€ 2.912 ± € 3,823 and € 2,590 
± € 3,210). The incremental effect of non-working status on direct medical cost 
was € 1.321 (95% CI: 121-2.520, p< 0,05). Employment condition and high levels of 
education had an incremental effect on indirect costs of € 2.616 (95% CI: 391-4.841, 
p< 0,05) and € 1.039 (95% CI: 135-1.943, p< 0,05). ConClusions: Socio-economic 
inequalities lead to a significant increase of direct medical cost of CKD. High edu-
cation and employment status of patients significantly increase the indirect cost 
component of CKD social cost.
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bACkgRound: Overactive bladder (OAB) symptoms still are not treated in Russian 
Federation in most cases though several medicines are available at the pharmaceuti-
cal market. Direct and indirect costs associated with treatment are important for 
decision makers in health care. objeCtives: To conduct cost analysis of solifenacin 
for OAB symptoms vs absence of pharmacotherapy from the Russian government 
perspective. Methods: A mathematical model was constructed to calculate direct 
and indirect costs associated with OAB for 1 year. Direct medical costs included 
OAB treatment with solifenacin when relevant, urine pads, treatment of compli-
cations and concomitant conditions (CCC) such as urinary infections, skin rash, 
depression and fractures. Indirect costs included productivity losses in patients 
of working ages. Data on incidence of CCC for solifenacin treatment and no treat-
ment strategies was derived from clinical studies. One-way sensitivity analysis was 
performed. Results: Direct medical costs are higher for soilifenacin strategy vs 
no treatment: € 567 and € 483 respectively with cost difference of € 84 per patient per 
year. But solifenacin appears to be cost saving strategy vs no treatment when total 
costs are taken into account: cost difference is € 40 per patient per year in favor of 
solifenacin. Solifenacin remains cost-saving option until the cost of urinary pads 
decreases twice from baseline or the solifenacin efficacy becomes less for 15% from 
baseline. ConClusions: Solifenacin seems to be an acceptable option for Russian 
healthcare from the government perspective.
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prescribed significantly higher number of drugs compared to those without diabetes 
and age ≤ 50 years. The top three prescribed medication groups were antianemic 
preparations (B03), minerals (A12) and vitamins (A11). Vitamin D analogues were 
prescribed to 31.3% of the patients. The predominantly prescribed vitamin D analogue 
was calcitriol. Around 91% of the patients were prescribed phosphate binders (PB). 
Calcium carbonate (88.8%) was the most commonly prescribed phosphate binder, 
whereas sevelamer and lanthanum were seldom prescribed. None of the patients 
was prescribed calcium acetate and aluminum-based PB. ConClusions: Patients 
with CKD stage 5D are prescribed higher number and variety of drugs for the man-
agement of comorbidities associated with kidney disease. Although non-calcium/
non-aluminum based PB have less side effects as compared to calcium-based PB, 
they are seldom prescribed.
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objeCtives: Chronic kidney disease (CKD) is one of the most commonly occurring 
non-communicable diseases in India. CKD is associated with significant morbidity, 
mortality and economic burden in India. The objective of the present study is to 
estimate the prevalence of CKD in India. Methods: A systemic search of published 
literature was carried out using PubMed, Elsevier ScienceDirect, Cochrane library 
databases and Google scholar (from 1990 to April 2015) by two independent review-
ers. Reference list of the related articles was also screened to find out the relevant 
studies. CKD definition of KDIGO guideline was used for inclusion criteria. Cochrane 
Q-statistics test and I2 statistics were used to assess the heterogeneity. Random 
effect model was used. Comprehensive Meta-Analysis software (Version 2.2, Biostat, 
Englewood NJ) was used. Results: Five studies were selected as per inclusion crite-
ria. These studies covered the different geographical regions in India. The numbers 
of participants ranged from 2091 to 5588. Pooled rate estimates suggest that 56.11% 
(95% CI, 48.46-63.75) of the patients were male. Hypertension and diabetes were 
found to be the most common comorbidities according to overall pooled estimates 
[48.67 (95% CI, 19.30-78.05) and 17.39 (95% CI, 6.67-28.12), respectively]. Modification 
of Diet in Renal Disease (MDRD) formula for GFR calculation was used by all studies. 
According to MDRD, CKD pooled prevalence in people over 18 years was found to be 
2.97% (95% confidence interval [CI], 1.38%-4.56%). However, Chronic Kidney Disease 
Epidemiology Collaboration (CKD-EPI) formula was used by two studies and pooled 
prevalence found to be 3.51%. Overall prevalence of end stage renal disease (ESRD) 
was 0.27% (95% CI, 0.06%-0.48%). Pooled estimate for the prevalence of protein urea 
was 6.98% (95% CI, 2.04%-11.91%). ConClusions: The prevalence of CKD, according 
to MDRD and CKD-EPI was 3% and 4%, respectively. Hypertension was found to be 
most commonly occurring co-morbidity (49%). About 7% of the Indian patients were 
found to have proteinuria.
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objeCtives: Our goal was to analyze the rising utilization and to provide a com-
parison between expected number of patients and expenditures described in the 
submitted budget impact analysis and the real expenditures of mirabegron for 
treatment of overactive bladder since its introduction in the Czech Republic in 
January 2014. Methods: The data source for our analysis was the business activ-
ity monitoring database of the General Health Insurance Company of the Czech 
Republic (VZP CR). VZP CR covers approximately 60 % of marketshare in the Czech 
Republic. Patient was defined as an insured person with a recorded prescription 
for mirabegron (G04BD12) during the observed period 01-12/2014. We identified 
the number of patients treated with mirabegron in the observed period and deter-
mined the real expenditures. We compared the real data with submitted BIA predic-
tions. Results: Since the introduction of mirabegron in January 2014 its utilization 
rose to 1.870 million DDD till 12/2014. There were 11 437 patients treated with mira-
begron and the real expenditures of VZP CR representing 60% were € 2.6 million 
(1EUR= 27,24CZK) in 2014, which strongly differed from the predicted number of 
patients (2026) and expenditures (€ 672t-€ 1.mil) presented in the base case budget 
impact analysis in the reimbursement decision published by State Institute of Drug 
Control (SUKL). ConClusions: There was a significant difference between expen-
ditures predicted in the submitted budget impact analysis and real expenditures. 
The real expenditures were almost 4 times higher than the base case predictions 
(2,5x higher when calculated with cost per patient estimation by SUKL) and more 
than 30% higher than the upper predictions for the first year. Expenditures in the 
first quarter 2015 (€ 1,5 million) have already reached the predictions for the whole 
2015 according the base case. Further analysis will follow to confirm this trend.
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objeCtives: Autosomal Dominant Polycystic Kidney Disease (ADPKD) imposes a 
significant economic burden on healthcare systems, particularly in advanced stages 
(5 or End Stage Renal Disease, ESRD). The aim of this model is to study the usual 
